The FDA approved the first generic version of Copaxone (glatiramer acetate injection) to treat patients with relapsing forms of multiple sclerosis (MS), giving a green light to the abbreviated new drug application (ANDA) filed by Sandoz Inc. to market Glatopa (glatiramer acetate injection, formerly M356), formulated as a once-daily 20 mg/mL injection.